June 2025
·
43 Reads
Critical Care
This page lists works of an author who doesn't have a ResearchGate profile or hasn't added the works to their profile yet. It is automatically generated from public (personal) data to further our legitimate goal of comprehensive and accurate scientific recordkeeping. If you are this author and want this page removed, please let us know.
June 2025
·
43 Reads
Critical Care
April 2025
·
4 Reads
Diagnostic Microbiology and Infectious Disease
February 2025
·
17 Reads
Journal of Clinical Virology
January 2025
·
25 Reads
·
1 Citation
Introduction Molecular surveillance is an important tool for detecting chains of transmission and controlling the HIV epidemic. This can also improve our knowledge of molecular and epidemiological factors for the optimization of prevention. Our objective was to illustrate this by studying the molecular and epidemiological evolution of the cluster including the new circulating recombinant form (CRF) 94_cpx of HIV‐1, detected in 2017 and targeted by preventive actions in 2018. Methods In June 2022, 32 HIV‐1 sequence databases from French laboratories were screened to identify all individuals who had acquired CRF94_cpx or a similar strain, whatever the date of diagnosis. Phylogenetic analyses were performed with the sequences identified, and biological parameters were collected at the time of diagnosis and after the start of treatment to analyse the evolution of the cluster. Full genomes were sequenced to characterize the new strains. Results We analysed 98 HIV‐1 isolates: 63 were CRF94, three were unclassifiable, and the other 32 formed a new cluster containing a new recombinant, CRF132_94B, derived from CRF94 and a subtype B strain. At least 95% of the individuals in both the CRF94 and CRF132 clusters were men who have sex with men (MSM), most of whom had acquired HIV less than 12 months before diagnosis. The number of CRF94 diagnoses declined drastically after 2018, but CRF132 strains spread widely between 2020 and 2022, into a different area of Ile‐de‐France region and within a younger population nevertheless aware of pre‐exposure prophylaxis. Higher viraemia, lower CD4 cell counts and delayed treatment efficacy suggested that CRF94 was more virulent than CRF132, possibly due to the F subtype fragment of the vif gene. Conclusions These findings highlight the role of the MSM transmission cluster in spreading HIV and new variants. They show also the benefits of cluster surveillance for improving the targeting of preventive interventions, detecting the emergence of new strains and enriching our knowledge on virulence mechanisms. However, these investigations require support with sufficient resources dedicated to a regional or national programme to be responsive and effective.
January 2025
·
23 Reads
Journal of Antimicrobial Chemotherapy
Background Therapeutic outcomes for patients infected by genetically divergent HIV-1/O are not well-known due to scarce data and the lack of an appropriate comparison with patients infected by pandemic HIV-1/M. We aimed to compare the immunological and virological response to cART between HIV-1/O and HIV-1/M patients followed in France. Methods All naïve HIV-1/O subjects initiating cART in France in ANRS-ORIVAO study were compared to naïve HIV-1/M subjects initiating cART in ANRS-COPANA cohort. Piecewise linear mixed-effect models and Kaplan–Meier survival curves were used to analyse immunological and virological response to cART overall (65 HIV-1/O versus 279 HIV-1/M), then only in patients initiating 2INTI + 1PI/r. Results Plasma viral load (pVL) at treatment initiation was 0.6 log10 copies/mL lower in HIV-1/O than in HIV-1/M patients (P = 0.004) in the overall population, but there was no difference in the time to pVL < 200 cp/mL after cART initiation (log rank test, P = 0.57). Meanwhile, baseline CD4 counts were lower in HIV-1/O (median 180/mm3) than HIV-1/M (248/mm3) patients (P = 0.001). At 4 months, the increase in CD4 counts did not differ (P = 0.96) between groups but remained lower in HIV-1/O patients beyond 4 months of treatment (P = 0.04). In PI/r population, baseline pVL was 1 log10 copies/mL lower for HIV-1/O than HIV-1/M patients, leading to significantly faster attainment of pVL < 200 cp/mL (log rank test: P < 0.001); immunological response to cART was similar. Conclusions HIV-1/O and HIV-1/M immunological and virological responses to cART did not differ when epidemiological characteristics of the patients were taken into account. In France, treating HIV-1/O following HIV-1/M guidelines leads to similar therapeutic outcomes.
December 2024
·
57 Reads
Clinical Microbiology and Infection
October 2024
·
25 Reads
Apmis
The Central African Republic (CAR) is characterized by widespread HIV epidemic with notable prevalence and genetic diversity. We herein analysed the genetic diversity of atypical non‐M HIV‐1 strains. In‐house serotyping assays for variants of HIV‐1 (M, N, O, P) and HIV‐2 were used to test a biological collection of 6092 HIV‐seropositive blood samples collected between 2003 and 2014 at the Institut Pasteur de Bangui. Samples indicative of recombinant M/O groups, HIV‐2, or those that yield doubtful/negative results underwent further PCR tests and sequencing. We found six atypical HIV strains: specifically, three (0.05%) HIV‐1 group O strains (subtype H) detected in samples from 2005, 2008 and 2009, alongside three (0.05%) HIV‐2 strains (two group A and one group B) identified in samples from 2007 and 2009. HIV‐1/O strains showed a genetic link to Cameroon and Gabon strains. This study highlights the dominance of HIV‐1/M in the CAR's HIV epidemic over time and underscores the infrequent occurrence of HIV‐1 group O and HIV‐2 strains. These findings validate the efficacy of WHO‐recommended HIV testing protocols and emphasize the need for adaptive surveillance and management strategies to confront the complexities introduced by the genetic diversity of HIV strains.
October 2024
·
152 Reads
·
16 Citations
The Lancet Infectious Diseases
August 2024
·
2 Reads
June 2024
·
1 Read
Médecine et Maladies Infectieuses Formation
... Chinese patients infected with CRF07_BC showed better correlation with immune recovery after ART compared to those infected with CRF01_AE [34,35]. Notably, while subtype B was associated with virulence enhancement, similar phenomenon was also observed in other CRFs in regions with high recombination rates [36]. This suggests that virulence enhancement may be a broader evolutionary adaptation rather than a subtype-specific trait, underscoring the need for longitudinal studies to track viral dynamics across different genetic backgrounds. ...
January 2025
... Currently, one of the most intriguing questions is the capability of RSV to establish a breakthrough infection, a term that describes RSV infection in infants who were administrated with nirsevimab. A study by Fourati et al. [122] analyzed 260 full-length RSV genome sequences from nirsevimab-treated breakthrough infections that occurred in France during the 2023-24 RSV season. In accordance with results obtained in nirsevimab late-phase clinical trials [32], low levels of nirsevimab-related resistance mutations were observed. ...
October 2024
The Lancet Infectious Diseases
... The recent Coronavirus disease 2019 pandemic caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has recently expanded the clinical scenarios of A. fumigatus infection to include COVID-19-associated pulmonary aspergillosis (CAPA) [4][5][6][7]. A multicenter study in France reported a 15% prevalence of CAPA in critically ill patients requiring invasive mechanical ventilation during the first wave [8], and a 5.1% prevalence in the Delta and Omicron waves, which rose to 9.1% among patients who required invasive mechanical ventilation [9]. Along with influenza-associated pulmonary aspergillosis, CAPA represents a form of viral-associated pulmonary aspergillosis in which a severe viral infection, likely by disrupting epithelial integrity and inducing a severe inflammatory response in critical patients, predisposes to the development of invasive fungal infection [7]. ...
April 2024
Annals of Intensive Care
... Esta pesquisa, realizada com estudantes universitários brasileiros, identificou que a maioria desse público tinha níveis de conhecimento adequados, atitudes e práticas positivas sobre a COVID-19, além de percepção de risco moderada sobre essa doença. Semelhantemente, outras pesquisas, realizadas com estudantes universitários, também identificaram conhecimentos adequados, atitudes e práticas positivas em relação à COVID-19 (13)(14)(15) . Esses achados podem estar relacionados ao fato de os en-trevistados desses estudos serem indivíduos com maior nível de escolaridade, visto que há influência dessa variável (16) . ...
November 2023
... In our study, we aim to evaluate the performance of a new cost-effective Mindray CL-900i-HIV Ag/Ab combo assay from Mindray-China as an alternative screening method to the well-established ARCHITECT ® HIV Ag/Ab combo assay [17][18][19] . In addition, we compared the performance of the Mindray CL-900i-HIV Ag/Ab combo assay against the gold standard INNO-LIA™ HIV I/II confirmatory assay 20 . We also included a surrogate reference method, PCR, in our evaluation. ...
July 2023
... The ΔHV69-70 deletion in the S gene, initially associated with the Alpha variant, has also been effective in differentiating between Omicron sublineages, such as BA.1 from BA.2 [29][30][31] and BA.4/BA.5 from BA.2 [32]. Here, our screening method, which utilizes the ΔHV69-70 deletion as a primary marker, demonstrated a predominance of BA.4/BA.5 over BA.2 from June to September 2022 (90.3% vs. 9.7%). ...
May 2023
... This huge genetic diversity of HIVs is mainly attributed to (i) their simian origins, involving at least 13 independent cross-species transmission events from great apes (HIV-1) or monkeys (HIV-2) to humans (Supporting Information S1: Figure 1), (ii) their replication properties characterized by a high replication rate with an important daily production of virions and a low fidelity of reverse transcriptase (RT), and (iii) the host selection pressure, which facilitates the establishment of quasispecies [8][9][10]. The co-circulation of different variants within the same geographic area often results in dual infections, as described with subtypes for HIV-1/M, subgroups for HIV-1/O or with HIV-1 and HIV-2 [11][12][13][14][15]. The dual infections may lead to the emergence of recombinant forms. ...
March 2023
... However, a follow-up have been performed for five patients monitored in France, giving first data on immune-virological response to combined ART (cART). For four of them (BCF204, RBF208, BCF212 and RBF243), the last point of follow-up showed a cART efficacy, demonstrating the efficiency of an adapted management taking into account the variant[85]. For the last one (RBF235), the last point of follow-up showed a virological failure after several distinct regimens (including NNRTIs), partially explained by an undiagnosed HIV-1/M+O dual infection and to adherence difficulties[68]. ...
March 2023
... Consequently, we could not analyze the severity of infection in the patients enrolled in this study. It was reported that patients infected with SARS-CoV-2 recombinant viruses showed low clinical severity until infection with the XD strain, a recombinant of the Delta and Omicron variants [21]. Thus, recombinant viruses originating from the Delta and Omicron variants may cause clinical symptoms with low severity. ...
May 2022
Clinical Infectious Diseases
... Another observational study specifically focused on the virological response of patients receiving the combination containing bictegravir [103]. We found 6% of the cohort received the combination, with 75% already in virological success from a previous antiretroviral combination. ...
Reference:
HIV-1 Non-Group M Strains and ART
April 2022
Journal of Antimicrobial Chemotherapy